Get the Stockscreener App
5.70
0.88%
0.05
Tango Therapeutics Inc stock is traded at $5.70, with a volume of 620.18K.
It is up +0.88% in the last 24 hours and up +75.93% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$5.65
Open:
$5.74
24h Volume:
620.18K
Relative Volume:
0.28
Market Cap:
$484.52M
Revenue:
$42.51M
Net Income/Loss:
$-116.49M
P/E Ratio:
-5.0893
EPS:
-1.12
Net Cash Flow:
$-120.82M
1W Performance:
+15.85%
1M Performance:
+75.93%
6M Performance:
+80.95%
1Y Performance:
-31.65%
1-Day Range:
$5.64
$5.96
1-Week Range:
$4.80
$5.96
52-Week Range:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
5.70 | 484.52M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Tango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com
Two Sigma Investments LP Sells 23,166 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World
What is B. Riley’s Forecast for TNGX Q2 Earnings? - Defense World
Squarepoint Ops LLC Makes New $40,000 Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Two Sigma Advisers LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DE - Defense World
11,198 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Ameriprise Financial Inc. - Defense World
Millennium Management LLC Invests $771,000 in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Tango Therapeutics: PRMT5 Data Readout Due In 2025 Is Critical (NASDAQ:TNGX) - Seeking Alpha
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Sold by Nuveen Asset Management LLC - Defense World
TNGX Stock Price and Chart — NASDAQ:TNGX - TradingView
Deutsche Bank AG Boosts Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Jane Street Group LLC Purchases 44,465 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Tango Therapeutics To Present At Goldman Sachs Global Healthcare Conference On June 10, 2025 - Nasdaq
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - GlobeNewswire
D. E. Shaw & Co. Inc. Takes $355,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Northern Trust Corp - Defense World
Tango Therapeutics doses first subject in trial for MTAP-deleted tumours - Yahoo Finance
Tango Therapeutics starts trial for brain cancer drug By Investing.com - Investing.com South Africa
Tango Therapeutics starts trial for brain cancer drug - Investing.com Australia
Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com
Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer - marketscreener.com
TNGX Initiates Phase 1/2 Trial for MTAP-Deleted Tumors | TNGX Stock News - GuruFocus
Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire
Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment - Stock Titan
Cantor Fitzgerald Issues Positive Estimate for TNGX Earnings - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TNGX - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st
Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Tango Therapeutics, Inc. (NASDAQ:TNGX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Barclays Remains a Buy on Tango Therapeutics (TNGX) - The Globe and Mail
Tango Therapeutics Extends Cash Runway Amid Clinical Progress - TipRanks
Tango Therapeutics (TNGX) Plans $400 Million Mixed Securities Sh - GuruFocus
Tango Therapeutics Files For Mixed Shelf Of Up To $400 Million - marketscreener.com
Tango Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Mi - GuruFocus
TNGX Reports Q1 Revenue Miss, Advances Cancer Treatments | TNGX Stock News - GuruFocus
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Misses Estimate, Revenue Falls Short at $5.4 Million - GuruFocus
Tango Therapeutics, Inc. SEC 10-Q Report - TradingView
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Barclays PLC Has $307,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics (TNGX) to Release Earnings on Monday - Defense World
Insights into Tango Therapeutics's Upcoming Earnings - Nasdaq
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of “Buy” by Analysts - Defense World
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tango Therapeutics Inc Stock (TNGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Douglas | General Counsel |
Feb 05 '25 |
Sale |
3.16 |
2,556 |
8,081 |
66,014 |
| Beckman Daniella | Chief Financial Officer |
Feb 04 '25 |
Sale |
2.99 |
4,284 |
12,801 |
154,232 |
| Beckman Daniella | Chief Financial Officer |
Feb 05 '25 |
Sale |
3.16 |
3,948 |
12,481 |
150,284 |
| Crystal Adam | See Remarks |
Feb 04 '25 |
Sale |
2.99 |
7,432 |
22,207 |
165,061 |
| Crystal Adam | See Remarks |
Feb 05 '25 |
Sale |
3.16 |
6,851 |
21,659 |
158,210 |
| Weber Barbara | Chief Executive Officer |
Feb 04 '25 |
Sale |
2.99 |
9,778 |
29,217 |
1,631,264 |
| Weber Barbara | Chief Executive Officer |
Feb 05 '25 |
Sale |
3.16 |
9,013 |
28,494 |
1,622,251 |
| Rothenberg Mace | Director |
Nov 18 '24 |
Buy |
3.78 |
10,000 |
37,800 |
31,250 |
| Rothenberg Mace | Director |
Nov 14 '24 |
Buy |
3.62 |
10,000 |
36,200 |
21,250 |
| EcoR1 Capital, LLC | 10% Owner |
Nov 06 '24 |
Sale |
3.28 |
1,494,558 |
4,896,023 |
11,836,178 |
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):